Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | CCR6 | P51684 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988449 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL12988450 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL12987484 | 0.92 | KDM4E (0.42) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL12987485 | 0.92 | KDM4E (0.42) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL12987578 | 0.92 | KDM4E (0.42) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL12987356 | 0.90 | IDH1 (0.38) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL12987358 | 0.90 | IDH1 (0.38) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL15420029 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL15420027 | 0.89 | KDM4E (0.39) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL15420051 | 0.85 | KDM1A (0.38) | CYP11B1CYP11B2IDH1KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | KDM4E 2112/4885ALDH1A1 143/4885HPGD 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.